Cycled Testosterone Replacement Study

The Effects of Cyclic Testosterone Administration on Muscle Function in Older Individuals

The purpose of this study is to determine whether testosterone (male hormone) therapy is effective if administered in a cyclic fashion (periodic dosing) compared to continuous dosing in men aged 60 to 85 years. Effectiveness will be determined based on improvements in body composition, muscle metabolism, muscle strength, and bone metabolism.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Men and women undergo a progressive reduction in lean muscle mass (sarcopenia) with advancing age regardless of their level of physical activity. A 12-yr longitudinal study in healthy sedentary older men showed a correlation between loss of muscle cross-sectional area and muscle strength of the thigh, quadriceps, and flexor muscles. Once weakened, older individuals are prone to falls that prevent independent living and diminish the quality of life. There is a need to develop therapies to counteract losses in skeletal muscle strength with aging. Studies show that exercise and testosterone administration increase skeletal muscle mass and strength in older men. However, the increase in muscle strength by testosterone in older men has not been consistent in all studies. Androgens increase muscle mass by either increasing muscle protein synthesis or inhibiting muscle protein breakdown. This proposal will investigate the hypothesis that cyclic testosterone administration (monthly on/off cycles) will preferentially increase muscle protein synthesis and result in a consistent and greater improvement in muscle strength than continuous testosterone administration.

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Galveston, Texas, United States, 77555
        • University of Texas Medical Branch

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Availability of transportation (i.e., subjects must be able to provide their own transportation to UTMB).

Exclusion Criteria:

  • Medications such as anticoagulants (Coumadin) and glucocorticoids.
  • History of angina that occurs with exertion or at rest.
  • History of myocardial infarction within the last 12 months.
  • Failure to successfully complete an exercise stress test using the Bruce protocol. Subjects that demonstrate ≥ 0.1 mV horizontal or downsloping ST segment depression, a drop in systolic blood pressure of ≥ 10 mm Hg, and/or frequent or repetitive arrhythmias (defined as ≥ 10 PVC/min, or couplets) during the stress test will be excluded.
  • LDL cholesterol above 200 mg/dL.
  • History of prostatic cancer.
  • Elevated prostate specific antigen (PSA) above 4.0 µg/L, or severe benign prostatic hypertrophy (BPH) by history (frequent urination, reduced stream).
  • Serum total testosterone concentrations of greater than 500 ng/dL.
  • Subjects who engage in high intensity, elite training on a regular basis.
  • Major medical illness such as diabetes, chronic obstructive pulmonary disease, or sleep apnea.
  • Recent history of smoking tobacco.
  • Hematocrit greater than 51%.
  • Morbidly obese older men (BMI > 35).
  • Hypertension: Blood pressure on three consecutive measurements taken at one week intervals that has a systolic pressure ≥ 140 or a diastolic blood pressure ≥ 90. Subjects will be included if they are on two or less blood pressure medications and have a blood pressure below these criteria.
  • History of hepatitis or a 3-fold elevation of liver function tests (Alk phos, ALT, AST).
  • Bone related disorders such as osteoporosis or parathyroid disease.
  • DEXA scans revealing lumbar spine T-scores of less than -2.5.
  • Subjects currently taking anti-bone-resorptive agents such as bisphosphonates, parathyroid hormone, or calcitonin.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Weekly placebo treatment for a duration of 5 months.
Weekly IM injections of sesame oil.
Other Names:
  • Sesame Oil
Experimental: Monthly Cycled Testosterone
A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
Weekly IM injections of sesame oil.
Other Names:
  • Sesame Oil
Weekly im injections of 100 mg testosterone enanthate.
Other Names:
  • Testosterone Enanthate
Experimental: Continuous Testosterone
Weekly testosterone treatment for a duration of 5 months
Weekly im injections of 100 mg testosterone enanthate.
Other Names:
  • Testosterone Enanthate

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months
Time Frame: 5 Months
The fractional synthetic rate (FSR) of mixed muscle is calculated by directly measuring the incorporation of L-[ring-13C6]-phenylalanine into protein (%/hr),, using the precursor-product model: FSR = [(EP2 - EP1)/(EM•t)]•60•100, where EP1 and EP2 are the enrichments of bound L-[ring-13C6]-phenylalanine in the first and second muscle biopsies, t is the time interval (min) between biopsies, and EM is the mean L-[ring-13C6]-phenylalanine enrichment in the muscle intracellular pool.
5 Months
Changes in Muscle Strength as Measured by Maximal Voluntary Contraction Tests (Arm Curl) at Baseline, One Month, Two Months, Three Months, Four Months, and at Five Months
Time Frame: 5 months
Maximum weight (pounds) lifted using Cybex weight machine in a single effort(1-RM) for upper extremities (biceps and triceps) and lower extremities quadriceps and hamstrings).
5 months
Changes in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA)
Time Frame: 5 months
Lean body mass is expressed in grams as calculated by Hologic DEXA.
5 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Bone Mineral Density as Measured by Dual Energy X-ray Absorptiometry (DEXA)
Time Frame: 5 months
Bone mineral density measure by measured by dual energy x-ray absorptiometry (DEXA)measured at baseline and a five months
5 months
Changes in Serum Markers of Bone Turnover.
Time Frame: 5 months

Measures of bone turnover markers in serum samples at baseline and at five months.The bone turnover markers analyzed include:

Markers associated with bone breakdown NTX (N-telopeptide) TRAP5b (tartrate-resistant acid phosphatase isoform 5b) Markers associated with bone formation Osteocalcin BAP (bone specific alkaline phosphatase) Regulators of bone formation iPTH (intact parathyroid hormone) increases in response to bone loss Calcitonin inhibits bone formation in response to elevated levels of serum calcium

5 months
9473Changes in Serum Inflammatory Biomarkers and Muscle Inflammatory Cytokines
Time Frame: 5 months
Serum inflammatory biomarkers (Interleukin B-1, 2,5,6,7,8,10,12 13, Interferon gamma, GM-CSF, and Tumor Necrosis Factor alpha)as measured by immunoassay at baseline and at five months
5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Randall J Urban, M.D., University of Texas

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2006

Primary Completion (Actual)

December 1, 2008

Study Completion (Actual)

December 1, 2008

Study Registration Dates

First Submitted

August 10, 2009

First Submitted That Met QC Criteria

August 11, 2009

First Posted (Estimate)

August 12, 2009

Study Record Updates

Last Update Posted (Estimate)

September 10, 2012

Last Update Submitted That Met QC Criteria

September 4, 2012

Last Verified

September 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • 01-302
  • GCRC 615
  • R01AG022023 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.